Supportive expressive group therapy did not prolong survival in metastatic breast cancer.
نویسندگان
چکیده
Patients 235 women (mean age 50 y) who had histological confirmation of breast cancer and had metastases outside of the breast and ipsilateral axilla. Exclusion criteria were central nervous system metastases; active psychosis, untreated major depression, or severe character disorder; planned participation in a therapist led support group for metastatic breast cancer outside of the study centre; residence > 1 hour travel from the study centre; life expectancy < 3 months; or inability to speak and read English. Follow up was complete for survival; follow up for psychosocial outcomes was 65% to 71%.
منابع مشابه
Supportive-expressive group therapy for women with metastatic-breast cancer: Improving access for Australian women through use of teleconference
While supportive-expressive group therapy (SEGT) has been found to be effective in significantly reducing distress associated with life threatening illness, the challenge in Australia is to develop a means of providing supportive interventions to rural women who may be isolated both by the experience of illness and geographical location. In this study an adaptation of SEGT was provided to women...
متن کاملChange in emotion-regulation strategy for women with metastatic breast cancer following supportive-expressive group therapy.
Four relatively independent emotion-regulation constructs (suppression of negative affect, restraint, repression, and emotional self-efficacy) were tested as outcomes in a randomized trial of supportive-expressive group therapy for women with metastatic breast cancer. Results indicate that report of suppression of negative affect decreased and restraint of aggressive, inconsiderate, impulsive, ...
متن کاملEmotional expression and diurnal cortisol slope in women with metastatic breast cancer in supportive-expressive group therapy: a preliminary study.
We examined coded emotional expression during an initial therapy session and its association with a known physiological risk factor for early death, aberrant diurnal cortisol slope, in women with metastatic breast cancer. Out of 64 women with metastatic breast cancer randomized to a multi-site clinical intervention trial of supportive-expressive group therapy (SET), a subsample of 29 met eligib...
متن کاملCisplatin Plus Gemcitabine for Breast Cancer Patients with Brain Metastases
Breast cancer is the second most common cause of brain metastases, approximately, 10-16% of the metastatic breast cancer patients develop BM. The survival time of the BC patients shorten rapidly after the development of BM. Whole brain radiotherapy is a standart therapy given to all patients with central nervous system (CNS) involvement. Metastasectomy and stereotactic radiosurgery are the othe...
متن کاملSALVAGE CHEMO THERAPY WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN (CAP) IN ADVANCED BREAST CANCER
Twenty-one patients with advanced breast cancer (7 premenopausal and 14 postmenopausal women) were treated with a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). The median age of the patients was 43 years (range 36-61). This therapy was repeated every 3 weeks. Nine patients (group 1) received CAP as primary therapy for metastatic breast cancer, and twelve patients (group...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Evidence-based nursing
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2002